Fingolimod ratiopharm 0.5 mg kapseli, kova Finlandia - finés - Fimea (Suomen lääkevirasto)

fingolimod ratiopharm 0.5 mg kapseli, kova

ratiopharm gmbh - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Fingolimod Zentiva 0.5 mg kapseli, kova Finlandia - finés - Fimea (Suomen lääkevirasto)

fingolimod zentiva 0.5 mg kapseli, kova

zentiva, k.s. - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Fingolimod Orion 0.5 mg kapseli, kova Finlandia - finés - Fimea (Suomen lääkevirasto)

fingolimod orion 0.5 mg kapseli, kova

orion corporation - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Fingolimod Mylan Unión Europea - finés - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kanssa vaikea ja nopeasti etenevä relapsoiva-remittoiva multippeliskleroosi on määritelty 2 tai enemmän invaliditeettiin sairauden pahenemisvaiheita on yksi vuosi, ja 1 tai enemmän gadolinium parantaa vaurioita aivojen mri tai merkittävä kasvu t2-leesio kuormitus verrattuna aiempaan tuoreeseen magneettikuvaukseen.

Fingolimod Mylan Unión Europea - finés - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Inzolfi 0.5 mg kapseli, kova Finlandia - finés - Fimea (Suomen lääkevirasto)

inzolfi 0.5 mg kapseli, kova

sandoz a/s - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Golpimec 0.5 mg kapseli, kova Finlandia - finés - Fimea (Suomen lääkevirasto)

golpimec 0.5 mg kapseli, kova

neuraxpharm sweden ab - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Gaxenim 0.5 mg kapseli, kova Finlandia - finés - Fimea (Suomen lääkevirasto)

gaxenim 0.5 mg kapseli, kova

bausch health ireland limited - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Teriflunomide Sandoz 14 mg tabletti, kalvopäällysteinen Finlandia - finés - Fimea (Suomen lääkevirasto)

teriflunomide sandoz 14 mg tabletti, kalvopäällysteinen

sandoz a/s - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi

Teriflunomide Mylan Unión Europea - finés - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomidi - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).